SCHEMBL30890716

SCHEMBL30890716

Cc1ccc2c(n1)OC1(C[C@@H](C(N)=O)N(C(=O)[C@H](CC3CC3)N(C)C(=O)[C@H](CC3CC3)NC(=O)OC(C)(C)C)C1)C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.32
▸ IDO1 P14902 1/20 0.31
▸ CTSS P25774 1/20 0.30
▸ CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27244994 0.91 OTUD7B (0.30) —
SCHEMBL27244982 0.91 OTUD7B (0.30) —
SCHEMBL27245011 0.90 — —
SCHEMBL27245019 0.90 — —
SCHEMBL30890777 0.89 — —
SCHEMBL30890705 0.88 AAK1 (0.32) AAK1CTSSCTSK
SCHEMBL30890631 0.88 AAK1 (0.32) AAK1CTSSCTSK
SCHEMBL27245114 0.86 CNR2 (0.31) —
SCHEMBL27245121 0.86 CNR2 (0.31) —
SCHEMBL27244806 0.85 OTUD7B (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
US-20240199647-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-20 — — US disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199647-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 AAK1 3988/4885IDO1 3030/4885CTSS 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback